



Our performance

Since October 2006, the UHCT Alliance has been implementing the following domestic or multi-national clinical trials. summary as of March 2013

Item	Details	Counts
Total		67
Type of study	Multi-national	38
	Asian	3
	Domestic	29
Cooperation of operability study of trail #	No. of Cooperation of operability study of trail for execution plan	9
Cooperation for selection of hospitals \$	No. of selection of hospitals by ours	41
	Days for selection of hospitals - without giving out paper, report for client and holiday	4-8
Briefing session for collaborate protocol %	No. of trial / No. of approved by IRB	37 / 47 &
Status of the implementation	Under review by IRB	8
	Approved by IRB	2
	Entry completed	45
	Abort	5
	Pending (Pre-IRB stage)	1
	No establishment	5
	The other	1
Meeting of improvement progress	Times / trials	17 / 42
	Requirements to hold a meeting 1) within 3 months from a clinical trial agreement 2) enrolled patients under 30% of contracted number of patients	March, September, December, 2008 and monthly in principle since then for projects meeting the requirements

- # As an optional case
- \$ Implementation after clients and our office have consulted
- % Project staff manage progress of the trail after meeting of protocol.
- & There are 6 cases without briefing session, since each study is assisted by only one establishment.

Executing rate of completed entry for clinical trial until March 2013

No	Serial No.	Indication	Type of trial Who	Who did select hospitals	Hospital for project	briefing session	No. of Participating hospitals	Months for entry	Total agreements	Total implementations	Executing rate
1	A#1	Parkinson(s) disease	Domestic	Client	Tokyo	Jan-07	5	12	60	54	90.0%
2	A#3	Autosomal dominant polycystic kidney disease	Global	Client	Chiba	Feb-07	3	16	23	22	95.7%
3	A#6	Hepatitis B	Domestic	Client	Tokyo	Feb-07	3	20	20	18	90.0%
4	A#7	Multiple sclerosis	Domestic	Client	TMD#	Aug-07	5	24	18	13	72.2%
5	A#8	Philadelphia chromosome-positive chronicmyeloid leukemia	Global	Alliance	Tokyo	Aug-07	6	12	21	19	90.5%
6	A#9	Diabetic peripheral neuropathic pain	Domestic	Alliance	Niigata	Sep-07	2	14	11	8	72.7%
7	A#10	Prostatic cancer	Domestic	Client	Tokyo	Aug-07	6	12	29	19	65.5%
8	A#13	Postherpetic neuralgia	Domestic	Client+Alliance	Tokyo	jun-07	5	16	15	8	53.3%
9	A#14	Chronic noncancerous pain	Domestic	Client+Alliance	Tokyo	jun-07	5	8	29	24	82.8%
10	A#15	Overactive bladder	Asian(4 Nationals)	Alliance	Shinshu	-	1	6	9	9	100%
11	A#16	Rheumatoid arthritis	Domestic	Alliance	TMD#	Nov-07	3	7	22	14	63.6%
12	A#17	Hepatocellular carcinoma	Global	Client	Chiba	Oct-07	2	14	18	13	72.2%
13	A#18	Rheumatoid arthritis	Domestic	Alliance	TMD#	Nov-07	3	13	16	14	87.5%
14	A#19	Prostatic cancer with bone metastasis	Global	Client	Tokyo	Dec-07	4	14	8	5	62.5%
15	A#20	Prostatic cancer without bone metastasis	Global	Client	Tokyo	Dec-07	4	28	9	7	77.8%
16	A#21	Multiple sclerosis	Domestic	Client	Tokyo	Feb-08	3	21	5	4	80.0%
17	A#23	Alzheimer(s) disease	Global	Alliance	Tokyo	Sep-08	2	23	10	10	100%
18	A#24	Acute pulmonary thromboembolism	Domestic	Alliance	Tokyo	jun-08	4	3	5	2	40.0%
19	A#25	Acute deep vein thrombosis	Domestic	Alliance	Tokyo	jun-08	4	12	13	9	69.2%
20	A#26	Chronic obstructive pulmonary disease	Asian(7 Nationals)	Alliance	Gunma	Sep-08	2	9	6	4	66.7%
21	A#27	MRSA infection	Domestic	Alliance	Niigata	Oct-08	3	13	13	7	53.8%
22	A#28	Chronic obstructive pulmonary disease	Global	Alliance	Chiba	Sep-08	2	12	14	10	71.4%
23	A#29	Influenza virus infections in high-risk patients	Domestic	Alliance	Niigata	-	1	6	3	2	66.7%
24	A#31	Chronic heart failure with high plasma BNP	Global	Alliance	Chiba	May-09	4	27	17	11	64.7%
25	A#32	Pulmonary arterial hypertension	Global	Alliance	Tokyo	-	2	36	4	4	100.0%
26	A#33	Pulmonary arterial hypertension	Global	Alliance	Tokyo	-	2	39	4	4	100.0%
27	A#34	Initial craniotomy	Domestic	Alliance	Niigata	Apr-09	2	12	27	27	100%

28	A#35	Chronic thromboembolic pulmonary hypertension	Global	Alliance	Tokyo	Nov-08	2	37	6	5	83%	
29	A#36	Chronic thromboembolic pulmonary hypertension	Global	Alliance	Tokyo	Nov-08	2	41	4	4	100%	
30	A#37	Chronic lymphocytic leukemia	Domestic	Alliance	Chiba	May-09	3	16	3	2	66.7%	
31	A#38	Non-small-cell lung cancer	Global	Alliance	Tokyo	Apr-09	4	5	11	8	72.7%	
32	A#39	Parkinson('s) disease	Domestic	Client	Chiba	jun-09	5	16	48	35	72.9%	
33	A#40	Parkinson('s) disease	Domestic	Client	Chiba	jun-09	5	25	31	26	83.9%	
34	A#42	cryptosporidiosis in children	Domestic	Alliance	-	-	1	20	1	1	100.0%	
35	A#44	Chronic obstructive pulmonary disease	Global	Alliance	Tokyo	Sep-10	4	9	13	8	61.5%	
36	A#45	Diabetic macular edema	Domestic	Alliance	Shinshu	-	4	14	23	19	82.6%	
37	A#46	Parkinson('s) disease	Domestic	Alliance	Tsukuba	Jan-11	5	22	21	15	71.4%	
38	A#47	Essential thrombocythemia	Domestic	Alliance	Chiba	-	2	8	6	6	100.0%	
39	A#49	Psoriasis	Global	Client	Gunma	Dec-10	2	9	8	8	100.0%	
40	A#50	Polycythemia vera	Global	Alliance	-	-	1	6	2	2	100.0%	
41	A#53	Acute symptomatic deep vein thrombosis	Domestic	Alliance	Gunma	-	3	14	14	10	71.4%	
42	A#54	Acute symptomatic pulmonary embolism	Domestic	Alliance	Gunma	-	5	13	11	10	90.9%	
43	A#55	hormone-insensitive prostate cancer	Domestic	Client	Tokyo	Nov-11	3	10	6	5	83.3%	
44	A#57	Essential thrombocythemia	Domestic	Alliance	Chiba	-	2	7	6	6	100.0%	
45	A#60	General anesthesia		Client	Tokyo	Oct-12	5	4	44	33	75.0%	
									Total	687	544	79.2%

Tokyo Medical and Dental University, University hospital of Medicine